key: cord-0887838-9p44l9jh
authors: AlQahtani, M.; Abdulrahman, A.; AlMadani, A.; AlAli, S. Y.; Al Zamrooni, A. M.; Hejab, A.; Wasif, P.; Conroy, R.; Atkin, S.; Otoom, S.; AlSayed, M. A.
title: Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
date: 2020-11-04
journal: nan
DOI: 10.1101/2020.11.02.20224303
sha: 746794ba09d99081b864653f9795ad0b3ca680d4
doc_id: 887838
cord_uid: 9p44l9jh

Background. Convalescent plasma (CP) therapy in COVID-19 disease has been suggested to improve clinical outcome in severe disease. This pilot study was designed to inform the design of a definitive phase 3 clinical trial. Methods. This was a prospective, interventional and randomized open label pilot trial involving 40 patients with COVID-19 who were requiring oxygen therapy and who had radiological evidence of pneumonia. Twenty COVID-19 patients received two 200ml transfusions of convalescent patient CP over 24 hours were compared with 20 patients who received routine care alone. The primary outcome was the requirement for ventilation. The secondary outcomes were white blood cell count, lactate dehydrogenase (LDH), C-reactive protein (CRP), Troponin, Ferritin, D-Dimer, procalcitonin, mortality rate at 28 days. Results. The CP group were a higher risk group with higher ferritin levels (p<0.05) though respiratory indices did not differ. The primary outcome measure (ventilation) was required in 6 controls and 4 patients on CP (risk ratio 0.67 95% CI 0.22 to 2.0, p=0.72); mean time on ventilation was 10.5 days in the control against 8.2 days in patients on CP (p=0.81). There were no differences in secondary measures at the end of the study. Two patients died in the control and one patient in the CP arm. Conclusion. There were no significant differences in the primary or secondary outcome measures between CP and standard therapy though fewer patients required ventilation and for a shorter period of time. The study showed that CP therapy appears to be safe and it is feasible to perform a definitive phase 3 clinical trial using this study protocol.

Coronavirus disease 2019 is caused by the severe acute respiratory syndrome 53 coronavirus 2 (SARS-CoV-2) and has developed into a pandemic with serious global public health 54 and economic sequelae. As of October 31st 2020, more than 46 million cases have been confirmed 55 worldwide leading to over 1,100,000 deaths 1 . There is no vaccine available, though several are 56 currently in development in clinical trials. There have been a number of reports of medication such 57 as remdesivir that have shown efficacy with shorter time to recovery having antiviral properties 58 with efficacy against SARS-CoV-2. 2 59 Plasma therapy using Convalescent Plasma (CP) transfusion refers to a form of passive 60 immunization, where neutralizing antibodies from a recovered donor are injected in the infected 61 patient with the aim of altering the course of the disease. This has been shown to be effective in 62 severe acute respiratory syndrome 3 , Ebola virus infection 4 and in H1N1 influenza 5 . More recently 63 there has been a report of the use of CP in the treatment of 5 ventilated COVID-19 patients with the 64 suggestion of expedited recovery as the patients improved 1 week after the transfusion 6 . A 65 randomized trial with CP therapy in severely and critically ill COVID-19 patients undertaken in 66

China was stopped early as recruitment slowed own due to the decrease in COVID-19 cases in 67 China 7 . An open label Expanded Access Program in the US studied the effect on CP on mortality in 68 more than 35,000 participants with COVID-19 that concluded that CP transfusion with high 69 antibody level and early during admission was associated with decreased mortality 8 . However, no 70 studies have been undertaken with CP therapy in hypoxic patients and therefore this pilot trial was 71 undertaken to inform the design of a definitive study. 72

Methods 74 75

This was a prospective, randomized, controlled open label pilot study involving 40 patients with 76 severe COVID-19 disease confirmed by RT-PCR testing 9 . All patients gave written informed 77 consent. This study was approved by the National COVID-19 Research Committee, and the Bahrain 78

Defence Force Hospital Ethics committee and was conducted in accordance with the Declaration of 79

Helsinki and local regulations. The trial was registered in clinicaltrials.gov with registration number 80 NCT04356534. The trial was conducted upon the approved protocol by the National Research and 81

Ethics committee. The study protocol is attached in the Appendix. 82

Participants 83 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 Patients were recruited from two medical centres. The study recruitment was from April, 2020, to 84 June, 2020. 85

Inclusion criteria were: (1) signed informed consent; (2) aged at least 21 years; (3) COVID-19 87 diagnosis based on polymerase chain reaction (PCR) testing; (5) Hypoxia (Oxygen saturation of 88 less than or equal 92% on air, or PO2 < 60mmHg in arterial blood gas, or arterial partial pressure 89 of oxygen (PaO )/fraction of inspired oxygen (FIO) of 300 or less) and patient requiring oxygen 90 therapy (6) pneumonia confirmed by chest imaging. 91

Exclusion criteria were the following: (1) Patients with mild disease not requiring oxygen therapy; 93

(2) Patients with normal CXR or CT scan; (3) Patients requiring ventilatory support (invasive or 94 non-invasive); (4) Patients with a history of allergy to plasma, sodium citrate or methylene blue, or 95 those with a history of autoimmune disease or selective IGA deficiency. 96

Following informed consent and screening, the patients were block randomised (in blocks of 4) by 98 computer-generated random numbering to either the standard therapy or CP arms ( Figure 1) . 99

Patients and clinicians were not blinded to the treatment given. 100

Patients who had recovered from COVID-19 and had been discharged from hospital for more than 2 102 weeks were approached to be volunteer donors. The criteria for donors included (1) ability to give 103 informed consent; (2) men or nulliparous women (all women had a pregnancy test except for 104 postmenopausal women); (3) PCR COVID-19 negative from respiratory tract; (4) patients were 105 symptom free; (5) patients above the ages of 21; (6) body weight more than 50kg; (7) met all donor 106 selection criteria employed for routine plasma collection and plasmapheresis procedures at the 107 collection centre. Convalescent plasma collection was performed followed by plasma extraction as 108 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. The dosage of CP was be 400 mL, given as 200ml over 2hrs over 2 successive days; the infusion 125 rate was monitored and amended if there was a risk of fluid overload. 126

Patients prior to CP therapy were on standard supportive treatment including control of fever 127 (paracetamol) and possible therapy including antiviral medications, Tocilizumab and antibacterial 128 medication. 129

The standard supportive treatment included control of fever (paracetamol) and possible therapy 131 including antiviral medications, Tocilizumab and antibacterial medication. 132

The primary end points were requirement for invasive or non-invasive ventilation, and, in patients 134 who required ventilation, the duration of ventilation. 135

Secondary outcome measures included C reactive protein, procalcitonin, lactate dehydrogenase, 137 troponin, ferritin, D-Dimer, brain natriuretic peptide, lactate changes and 28day mortality rate 138

White blood cell count was measured by flow cytometry, lactate dehydrogenase (LDH) was 140 measured using a kinetic method, C-reactive protein (CRP) and D-Dimer measured by an immuno-141 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224303 doi: medRxiv preprint turbidimetric assay, Troponin, Ferritin and procalcitonin were measured by an 142 electrochemiluminescence immunoassay according to the manufacturers' instructions. 143 144 145 Secondary analysis 146 147

Measurement of the effect of early CP transfusion (less than 3 days from admission) compared to 148 late transfusion for the requirement of ventilation was undertaken. Further analysis was done to 149 compare the mean antibody level of the CP on the requirement for ventilation. 150

Power and sample size for pilot studies was based on Birkett and Day 10 . They concluded that a 153 minimum of 20 degrees-of-freedom was required to estimate effect size and variability for normally 154 distributed variables and hence 20 patients per group were recruited in this study; no allowance was 155 made for dropouts, who are unlikely to be an issue in a study of this sort. 156

Baseline continuously distributed data are presented as means and standard deviations unless the 157 data are skewed in which case the data median (25th/75th centiles) are presented; categorical data 158 are shown by number and percent. Intention to treat analysis was used throughout. 159

For all statistical analyses, a two-tailed P <0.05 is considered to indicate statistical significance. 160

Time to event analysis and logistic regression are used to analyse event-related outcomes. Effect 161 size for secondary outcomes is shown as the Hodges-Lehmann median difference and its associated 162 confidence interval, calculated using the community-contributed Stata command cendiff 11 . It should 163 be noted that this is the median of all pairwise differences between the groups and does not 164 correspond to the difference between the medians of the two groups. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224303 doi: medRxiv preprint

The participant demographic, clinical and biochemical characteristics are shown in Table 1 and 171 medication after randomization is shown in Table 2 . The two groups showed similar baseline 172 epidemiological characteristics. The CP group showed higher ferritin levels (p=0.049); however, 173 respiratory indices did not differ. There were more men than women, reflecting the demographics 174 of the workforce in Bahrain. 175 A total of 6 controls (30%) and 4 CP patients (20%) were ventilated (risk ratio 0.67 95%CI 0.22 -176 2.0, p=0.72). Primary outcome measure, time to ventilation was not different (P=0·52, logrank test; 177

Figure 2); time on ventilation did not differ (10.5 days control; 8.25 days CP (exact p=0.809)). 178

Steroids were used in 3 control patients and none of the CP patients with no difference between 179 groups (P=0·342). To detect a difference at 90% power, alpha 0.05, with a risk ratio of 0.7 and risk 180 in control 20%, a sample size of 822 in each group would be needed. 181 Table 3 shows the medians of secondary outcomes at discharge in patients who were discharged 182 alive (18 control and 19 CP). The table also shows the Hodges Lehman median differences between 183 the groups, with their associated confidence intervals. Significance levels are based on the 184

Wilcoxon Mann-Whitney rank sum test. 185

The CP antibody level was available for 13 participants (mean 63.8 AU/mL± sd 46.8, 186 median 54.5). The patients who required a ventilator and received CP had a mean antibody level 187 of 84.95 AU/mL (SD 13.72, SE 7.9, N=3), whilst those that did not require 188 mechanical ventilation had a mean of 57.48 AU/mL (SD 51.8, SE 16.4, N=10; p=0.24) . 189 30% of patients who received early CP (less than 3 days from admission) required ventilation. None 190 of the patients who received CP after 3 days from admission required ventilation. Patients who 191 received early CP had a mean antibody level of 82 AU/mL (SD 23, SE 9.5, N=6). Those who 192 received CP after 3 days had a mean titre 49 AU/mL (SD 58, SE 22, N=7) (p=0.06, rank sum test). 193

Two patients died in the control and one patient in the CP arm and their secondary outcome data 194

were not included in Table 3 195 196 197 Three patients treated with plasma reported adverse events during the study that were not 198 considered to be related to therapy: one with diarrhoea and vomiting that settled spontaneously; one 199 with constipation and one desaturated transiently after the infusion. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224303 doi: medRxiv preprint

In this pilot study, the CP group appeared to have a higher systemic inflammatory response shown 204 by the increased ferritin levels and more patients with chronic lung disease were included, a known 205 risk factor for more severe disease 12 ; however, respiratory indices did not differ between the 206 groups. While the CP therapy group had fewer patients deteriorating to ventilation (primary 207 outcome), and the duration of ventilation was less, this did not differ significantly from the standard 208 therapy group. These results are in accordance with a larger study done in China by Ling Li et al, 209 that was stopped prematurely due to the decrease in COVID 19 cases 7 ; however, as shown in this 210 pilot, it is likely that trial was underpowered as an estimated sample size of over 822 in each group 211 may be required to show a difference. 212

Steroids have been shown to be effective in COVID-19 13 ; however, at the time of the study this 213 evidence was not known and hence steroids were used at the discretion of the physicians. Steroids 214 were used on 3 patients on standard therapy, none of the CP patients received steroids, but the 215 sample size was inadequate to justify a hypothesis test. Of note, in the study by Ling Li et al, 216 45.6% CP arm and 32.7% of control arm were given steroids that may have masked the CP effect 7 , 217 and in addition, the impact of Chinese herbal medicines (used in over 50% of patients) is unclear in 218 COVID-19 7 . In this study, no subject received Remdesivir, but Hydroxychloroquine, Ribavirin and 219

Lopinavir/ritonavir were used, though to date they have not been reported to be effective in 220 COVID-19 infection 14 15 16 . This pilot in accord with others 7 17 18 indicated that CP therapy was 221 safe with only three transient adverse reactions being recorded. The safety of plasma was assessed 222

in an observational study in 20,000 hospitalized patients in the US and it reported low incidence 223 (<1%) of serious adverse events 18 . Sanfilippo et al highlighted that plasma transfusion can be 224 harmful in COVID19 as plasma contains procoagulant factors, and COVID19 represents a unique 225 scenario as they tend to have an increased risk for thrombosis 19 . The prothrombotic risk with 226 plasma transfusion was not investigated in our study nor in other studies, and it has been suggested 227 recently that the potential harm of the non-immune components of convalescent plasma should be 228 studied, especially the prothrombotic risk. 20 229 230 Patients who received early CP (less than 3 days from admission) had a higher mean antibody 231 level in the transfused plasma, than those that received CP after 3 days, though the difference was 232 not significant. A previous study reported that patients who received early CP and with 233 higher antibody titres showed a better clinical outcome 8 ; however, this pilot was not adequately 234 powered to test the effect of early plasma in comparison to late plasma administration. 235 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi. org/10.1101 org/10. /2020 The CP collected from donors showed variations in mean antibody level, some extending to very 236 low levels. The variability in the antibody level can have an effect on the effectiveness of plasma 237 and can underestimate the effect of CP in this trial. The FDA have given recommendations to use 238 CP with high antibody titre only 21 , to prevent transfusion of CP with low antibody levels that can 239 be ineffective. 240

Our trial result was also in agreement with a recent randomized trial conducted in India in 464 241 adults with COVID19. Agarwal et al mentioned that convalescent plasma was not associated with a 242 reduction in progression to severe covid-19 or all-cause mortality. A subgroup analysis showed no 243 difference in the outcome even after stratifying on the presence neutralizing antibody levels (> 244 1:20). 22 245 A randomized trial comparing convalescent plasma with standard of care therapy in patients 246 hospitalized for COVID-19 in the Netherlands was stopped early after observing that more than 247 79% of patients randomized to the plasma arm had median antibody titres comparable to the plasma 248 donors, prior to receiving the plasma transfusion. There was no significant difference in the median 249 neutralizing antibody titre between recipients and donors, despite patients being randomized within 250 10 days of symptom onset. This may indicate that measuring the antibody titre of patients is 251 important in order to select those patient with low a antibody titre that might benefit from CP 252 transfusion. 23 253

The main limitations of this study were that it was pilot whose main purpose was to guide the 254 design of a definitive study of CP therapy, and as a consequence it lacks the statistical power to 255 conduct outcome hypothesis tests. Determination of the optimal antibody titre from the donors 256 should also be undertaken that was not done in this study, as well a measurement of antibody titre in 257 the recipients before and after the infusions. Moreover, the quantification method for the antibody 258 levels could have been improved and using the neutralizing antibody titre would have been more 259 appropriate; however, at the time of the study, an authorized neutralizing antibody titre test was not 260 available. Furthermore, the antibody titres were also not measured for our patients on 261 randomization. 262

This pilot study showed that it is feasible to perform a phase 3 randomized controlled trial on a 263 larger sample size to determine the effect of plasma, using the current protocol. For a definitive 264 study, the following are suggested modifications 1) Including only plasma with high titre antibody, 265 (defined as ≥250) 21 ; 2)Include only recipients with low antibody titre levels; 3)Serial monitoring of 266 PaO2:FiO2 Ratio in patients ; 4)Using of "hard" composite outcome of death or severe ARDS 267 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224303 doi: medRxiv preprint denoted by PaO2:FiO2 Ratio <100 ; 5)Studying safety endpoint regarding thrombosis in patients 268 using plasma. 269

In conclusion, there were no significant differences in the primary or secondary outcome measures 271 between CP and standard therapy though fewer patients required ventilation and for a shorter period 272 of time. The study showed that CP therapy appears to be safe and it is feasible to perform a 273 definitive phase 3 clinical trial using this study protocol. 274

We are very grateful for the support in this trial by our fellow colleagues from physicians and 277 nurses who have worked hard throughout the pandemic and specially during the trial period. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224303 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224303 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224303 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 4, 2020. ; https://doi.org/10. 1101 /2020 

Coronavirus Update (Live): 46,432,714 Cases and 1,200,927 Deaths from COVID-19 313 Virus Pandemic -Worldometer

Remdesivir for the Treatment of Covid-19 -316 Preliminary Report. The New England journal of medicine

Retrospective comparison of convalescent plasma with 319 continuing high-dose methylprednisolone treatment in SARS patients. Clinical microbiology 320 and infection : the official publication of the European Society of Clinical Microbiology and 321 Infectious Diseases

Evaluation of convalescent whole blood for 323 treating Ebola Virus Disease in Freetown, Sierra Leone. The Journal of infection

Convalescent plasma treatment reduced mortality in 326 patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical infectious 327 diseases : an official publication of the Infectious Diseases Society of America

Treatment of 5 Critically Ill Patients With COVID-19 With 330 Convalescent Plasma

Effect of Convalescent Plasma Therapy on Time to Clinical 333 Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical 334

Effect of Convalescent Plasma on Mortality 337 among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv : the 338 preprint server for health sciences

Detection of 2019 novel coronavirus (2019-nCoV) 340 by real-time RT-PCR

Internal pilot studies for estimating sample size

Confidence intervals for rank statistics: Percentile slopes, differences, and 345 ratios

Among Patients with Coronavirus Disease 2019 -United States

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with 352

The New England journal of medicine

Triple combination of interferon beta-1b, lopinavir-355 ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an 356 open-label, randomised, phase 2 trial

Azithromycin in Mild-to-Moderate Covid-19. The New England journal of medicine

Early safety indicators of COVID-19 362 convalescent plasma in 5000 patients

Safety Update: COVID-19 Convalescent Plasma 365 in 20,000 Hospitalized Patients

Convalescent plasma for COVID-19: the risk 368 of pulmonary embolism should not be underestimated! Crit Care

Convalescent plasma is ineffective for covid-19

Administration

Convalescent 376 plasma in the management of moderate covid-19 in adults in India: open label phase II 377 multicentre randomised controlled trial (PLACID Trial)

Convalescent Plasma for COVID-380 19. A randomized clinical trial